Observational studyOncotarget2022

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.

Reyes Bernabé-Caro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.